NCT01136551

Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: Male
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.

Conditions

• Healthy
• Bioavailability

Interventions

Type	Name	Description
DRUG	Huperzine A	Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-01-01
• Completion: 2011-04-01
• First posted: 2010-06-03
• Last updated: 2010-06-03

Locations

1 site across 1 country: Israel